NCT04971720View on ClinicalTrials.gov

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
ObesityCardiovascular DiseasesHypertensionNocturnal Blood PressureNatriuretic PeptidesRenin-Angiotensin-Aldosterone System
Interventions
DRUG

Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet

The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.

DRUG

Valsartan 80 mg Oral Tablet

The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.

Trial Locations (1)

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Alabama at Birmingham

OTHER